| Summary: | <p><strong>Introduction</strong>: The infection by the Hepatitis C virus (HCV) is one of the most common causes of liver's disease worldwide. Approximately between 60-80% of infected people, infection becomes chronic, and can lead in the long-term to the development of other liver's diseases such as cirrhosis and the hepatocellular carcinoma. Treatment of HCV has progressed enormously in the last decade, concluding with the development of Direct-acting Antiviral Agents (DAA), which has achieved cure rates over 90%. <strong><br /> Objective:</strong> To know the different available treatments options as well as which will be available in a near future. <strong><br /> Materials and methods:</strong> Several systematic searches were made in the PubMed database; in the articles from the "liver meeting" congress of AASLD (American Association for the Study of Liver Diseases) in November 2014 and in the EASL (European Association for the Study of Liver) guide. <strong><br /> Development:</strong> The arrivals of new drugs with new therapeutic strategies have made this therapy more complex, and for that reason it is necessary to have knowledge of these drugs and their possible combinations. <strong><br /> Conclusions:</strong> The excellent results of the therapy with AAD have made a huge change in therapeutic recommendations, making possible shorter therapies, better tolerated by patients and safer for health.</p><p><strong>Keywords</strong>: Hepatitis C virus, genotypes, direct acting antivirals, pharmacotherapy, mechanism of action, sofosbuvir, sustained virological response.</p>
|
|---|